Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTOR Gene Mutation”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Early research (Phase 1)Study completedNCT01596140
What this trial is testing

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Who this might be right for
Advanced CancerSolid Tumor
M.D. Anderson Cancer Center 27
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Not applicableLooking for participantsNCT04395495
What this trial is testing

RASopathy Biorepository

Who this might be right for
RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more
Children's Hospital Medical Center, Cincinnati 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03047213
What this trial is testing

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaMetastatic Transitional Cell CarcinomaMetastatic Urothelial Carcinoma+3 more
National Cancer Institute (NCI) 17
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Ended earlyNCT02315625
What this trial is testing

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT05103358
What this trial is testing

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Who this might be right for
TumorTumor, SolidMetastasis+18 more
Aadi Bioscience, Inc. 120
Not applicableEnded earlyNCT05571670
What this trial is testing

Bile Acids in Acute Insulin Resistance

Who this might be right for
PI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more
Columbia University 3
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Testing effectiveness (Phase 2)Ended earlyNCT00877773
What this trial is testing

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 44
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Testing effectiveness (Phase 2)Study completedNCT06132932
What this trial is testing

WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
PIK3CA Mutation-Related Tumors
Shanghai Jiatan Pharmatech Co., Ltd 38
Testing effectiveness (Phase 2)Study completedNCT03190174
What this trial is testing

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Who this might be right for
Ewing SarcomaPEComaEpithelioid Sarcoma+11 more
Sarcoma Oncology Research Center, LLC 34
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Early research (Phase 1)Ended earlyNCT05840510
What this trial is testing

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

Who this might be right for
Solid Tumor, AdultNSCLCAdvanced Cancer+2 more
Mirati Therapeutics Inc. 6
Testing effectiveness (Phase 2)Study completedNCT04094675
What this trial is testing

Sirolimus for Cowden Syndrome With Colon Polyposis

Who this might be right for
PTEN Gene MutationPTEN Hamartoma Tumor SyndromePTEN Hamartoma Syndrome+4 more
Ohio State University 5
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Testing effectiveness (Phase 2)Ended earlyNCT03740100
What this trial is testing

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

Who this might be right for
HNSCC
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Next Page